![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Tag: Coronavirus information (COVID-19)
News
EMA issues advice on the use of Celltrion’s anti-COVID-19 monoclonal antibody treatment regdanvimab for COVID-19 patients in the EU
Celltrion Group announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for the...
Clinical Trials
CyanVac Selects Exothera for the Development and GMP Mfg anufacturing of its COVID-19 Intranasal Vaccine Candidate for Phase III Clinical Trial is Europe and...
CyanVac LLC, a vaccine company, announced that they have selected Exothera S.A., a full-service Contract Development and Manufacturing Organization (CDMO), for the development and...
Drug Research
Moderna Announces New Supply Agreement with the Philippines for 7 Million Additional Doses of COVID-19 Vaccine Moderna
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the Philippines has secured 7 million additional doses of COVID-19...
News
Roche’s antibody cocktail lowers hospitalisation by 70% in Covid-19 patients
Roche has reported that the Phase III REGN-COV 2067 trial of investigational antibody cocktail of casirivimab and imdevimab met its primary endpoint of reducing...
Clinical Trials
Phase 3 Trial Shows REGEN-COV antibody Cocktail Reduced Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients
Regeneron Pharmaceuticals, Inc. announced positive topline results from the largest trial to date assessing a COVID-19 treatment in infected non-hospitalized patients (n=4,567). This definitive...
Clinical Trials
BioAge Initiates Phase 2 Trial of BGE-175 to Treat COVID-19 by Reversing Immune Aging
BioAge Labs, Inc., a clinical-stage biotechnology company developing medications that target aging to treat severe diseases, announced that it has commenced a Phase 2...
Clinical Trials
CureVac Expands CVnCoV COVID-19 Vaccine Candidate Clinical Trial Analyses to Include Phase 2b/3 Variant Specification
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced plans to expand and...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read